BCM
BBIO icon

Boone Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Boone Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.3M Buy
339,720
+110,891
+48% +$7.77M 5.92% 9
2026
Q1 		$17M Buy
228,829
+43,866
+24% +$3.18M 5.21% 10
2025
Q4 		$14.1M Sell
184,963
-275,319
-60% -$18.1M 4.44% 12
2025
Q3 		$23.9M Buy
+460,282
New +$22.4M 7.84% 5
2024
Q1 		– Sell
-440,845
Closed -$17.8M – 23
2023
Q4 		$17.8M Buy
440,845
+127,464
+41% +$3.83M 4.15% 13
2023
Q3 		$8.26M Buy
+313,381
New +$8.89M 2.61% 13

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Boone Capital Management's BBIO Position: Q2 2026 in Review

Boone Capital Management increased its BridgeBio Pharma (BBIO) stake by 48% in Q2 2026, buying an estimated $7.77M and bringing the position to 339,720 shares worth $25.3M. The position accounts for 5.92% of the portfolio, ranked #9.

Boone Capital Management first reported a position in BBIO in Q3 2023 and has held it in 6 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Boone Capital Management held 339,720 shares of BridgeBio Pharma worth $25.3M as of Q2 2026.
  • Boone Capital Management bought 110,891 BridgeBio Pharma shares in Q2 2026, an estimated $7.77M.
  • BridgeBio Pharma made up 5.92% of Boone Capital Management's portfolio in Q2 2026, its #9 holding.
  • Boone Capital Management first reported a position in BridgeBio Pharma in Q3 2023 and has held it in 6 quarters since.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Boone Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.